family with sequence similarity 136 member B, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM136BP profile across patient tissues and cancer cell-line models. FAM136BP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FAM136BP is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, FAM136BP RNA expression shows 5,476 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, and STAD as cancer lineages where FAM136BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM136BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM136BP survival associations across molecular data types. FAM136BP RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM136BP RNA expression–survival associations across cancer types. High FAM136BP expression shows unfavorable associations in LIHC, KIRP, READ and UVM, but favorable associations in COAD and MESO. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for FAM136BP RNA expression.
This table summarizes FAM136BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM136BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM136BP shows higher tumor expression in COAD, LUAD, LUSC, UCEC, ESCA and LIHC. The COAD box plot shows higher FAM136BP RNA expression in tumor versus normal tissue (log2 FC = +0.438, t-test p = .001).
This table shows molecular features associated with FAM136BP in patient tissues and cancer cell lines. In patient samples, FAM136BP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
